title: Optimization of incubation temperature in embryonated chicken eggs inoculated with H9N2 vaccinal subtype of avian influenza virus.
abstract: There are little information about growth properties of low pathogenic (LP) avian influenza virus (AIV) in embryonated chicken eggs (ECEs) at different incubation temperatures. Knowledge of this information increases the quantity and quality of antigen in vaccine production process. For this purpose, 10(-5) dilution of AIV (A/Chicken/Iran/99/H9N2) was inoculated (Intra-allantoic) into 400, 11-day old specific pathogen free (SPF) ECEs in the 0.1 mL per ECE rate and incubated in 32, 33, 34, 35, 36, 37.5, 38, 39 ˚C for 72 hr in 65% humidity. Early death embryos in first 24 hr were removed. Amnio-allantoic fluid was withdrawn into the measuring cylinder, and tested for hemagglutination (HA) activity and egg infective dose 50 (EID50). The utilizable ECEs and amnio-allantoic fluid volume was significantly increased in 35 ˚C, (p < 0.05). Significant difference in HA and EID50 titers, were seen only in 39 ˚C group. Therefore, 35°C is an optimum temperature for incubation of inoculated ECEs.
authors: Department of Research and Development, Razi Vaccine and Serum Research Institute, Marand, Iran.
authors: Iraj
authors: I
authors: Khalili
authors: Department of Research and Development, Razi Vaccine and Serum Research Institute, Marand, Iran.
authors: Rahim
authors: R
authors: Ghadimipour
authors: Department of Research and Development, Razi Vaccine and Serum Research Institute, Marand, Iran.
authors: Ali
authors: A
authors: Ameghi
authors: Department of Research and Development, Razi Vaccine and Serum Research Institute, Marand, Iran.
authors: Saeed
authors: S
authors: Sedigh-Eteghad
keywords: Inactivated influenza vaccine; Incubation temperature; Optimization
references: J Exp Biol. 2002 Sep;205(Pt 18):2925-33
references: 12177157
references: J Bacteriol. 1958 Jun;75(6):707-12
references: 13549376
references: J Clin Microbiol. 2006 Apr;44(4):1596-7
references: 16597906
references: J Gen Virol. 2011 Jan;92(Pt 1):36-50
references: 20861321
references: Vaccine. 2003 Jul 4;21(23):3212-8
references: 12804850
references: Curr Opin Pharmacol. 2001 Oct;1(5):491-6
references: 11764775
references: Arch Virol. 2011 Jun;156(6):987-94
references: 21302122
references: J Exp Med. 1950 Feb 28;91(3):321-9
references: 19871708
references: Expert Rev Mol Med. 2010 Apr 29;12:e14
references: 20426889
references: Poult Sci. 1997 Jan;76(1):124-33
references: 9037699
references: J Anat. 2007 Jun;210(6):741-8
references: 17523938